Tompkins Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Tompkins Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.86K	Hold	13	–	–	﹤0.01%	469
2026 Q2	$8.11K	Buy	+13	New	+$8.85K	﹤0.01%	469
2025 Q2	–	Sell	-50	Closed	-$31.7K	–	570
2025 Q1	$31.7K	Buy	+50	New	+$34.4K	﹤0.01%	365
2021 Q4	–	Sell	-15	Closed	-$9K	–	389
2021 Q3	$9K	Buy	+15	New	+$9.31K	﹤0.01%	328
2021 Q1	$7K	Hold	15	–	–	﹤0.01%	378
2020 Q4	$7K	Buy	+15	New	+$8.1K	﹤0.01%	385
2014 Q1	–	Sell	-91	Closed	-$25K	–	537
2013 Q4	$25K	Hold	91	–	–	0.01%	337
2013 Q3	$28K	Buy	+91	New	+$23.9K	0.01%	319

Other funds holding REGN

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Tompkins Financial's REGN Position: Q3 2026 in Review

Tompkins Financial held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 13 shares worth $9.86K. The position accounts for ﹤0.01% of the portfolio, ranked #469.

Tompkins Financial first reported a position in REGN in Q3 2013 and has held it in 8 quarters since. The position peaked at $31.7K in Q1 2025. 167 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Tompkins Financial held 13 shares of Regeneron Pharmaceuticals worth $9.86K as of Q3 2026.
Tompkins Financial left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Tompkins Financial's portfolio in Q3 2026, its #469 holding.
Tompkins Financial first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 8 quarters since.
Tompkins Financial's Regeneron Pharmaceuticals position peaked at $31.7K in Q1 2025.
167 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Tompkins Financial's 13F filing for Q3 2026, filed 5 Oct 2026.